Quidel to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on February 12, 2013
SAN DIEGO, CA, Jan 31, 2013 (MARKETWIRE via COMTEX) --
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid
diagnostic testing solutions and cellular-based virology assays, will
release fourth quarter and full year 2012 financial results after
market close on Tuesday, February 12, 2013.
Following the release of results, Douglas Bryant, president and chief
executive officer, and Randy Steward, chief financial officer, will
host an investment community conference call beginning at 5:00 p.m.
Eastern Time (2:00 p.m. Pacific Time) to discuss the results and
answer questions. During the conference call, the company will also
discuss business and financial developments and trends. The company's
statements may contain or constitute material information that has
not been previously disclosed.
To participate in the live call by telephone from the U.S., dial
866-730-5769, or from outside the U.S. dial 857-350-1593, and enter
the pass code 75220493.
A live webcast of the call can be accessed at http://www.quidel.com,
and the Web site replay will be available for 14 days. The telephone
replay will be available for 48 hours beginning at 7:00 p.m. Eastern
Time (4:00 p.m. Pacific Time) on February 12 by dialing 888-286-8010
from the U.S., or 617-801-6888 for international callers, and
entering pass code 87777394.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of
people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
QuickVue(R), D3(R) Direct Detection and Thyretain(R) leading brand
names, as well as under the new Sofia(R) and AmpliVue(R) brands,
Quidel's products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's research and development
engine is also developing a continuum of diagnostic solutions from
advanced lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians' offices and hospital and reference laboratories. For more
information about Quidel's comprehensive product portfolio, visit
www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Chief Financial Officer
Media and Investors Contact:
[ InfoTech Spotlight's Homepage ]